β-amyloid (Aβ)42(43), Aβ42, Aβ40 and apoE immunostaining of plaques in fatal head injury

Neuropathology and Applied Neurobiology

Volumn 26, Issue 2, 2000, Pages 124-132

  Horsburgh, K ^a   Cole, G M ^b   Yang, F ^b   Savage, M J ^c   Greenberg, B D ^c   Gentleman, S M ^d   Graham, D I ^a   Nicoll, J A R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CEPHALON INC   (United States)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

amyloid; Alzheimer's disease; Apolipoprotein E genotype; Head injury; Human; Immunohistochemistry

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA PROTEIN (1 43); AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); AMYLOID BETA-PROTEIN (1-43); DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ADULT; AGED; ARTICLE; BRAIN CORTEX; GENOTYPE; HEAD INJURY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENILE PLAQUE; TEMPORAL CORTEX; ADOLESCENT; ALZHEIMER DISEASE; BRAIN; BRAIN LEVEL; CHEMISTRY; GENETICS; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; SILVER STAINING;

ADOLESCENT; ADULT; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIBODIES, MONOCLONAL; APOLIPOPROTEINS E; BRAIN; BRAIN CHEMISTRY; CRANIOCEREBRAL TRAUMA; GENOTYPE; HUMANS; MIDDLE AGED; PEPTIDE FRAGMENTS; SENILE PLAQUES; SILVER STAINING;

EID: 0033625502     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2990.2000.026002124.x     Document Type: Article

References (46)

1. 1 Cummings BJ, Satou T, Head E et al. Diffuse plaques contain C-terminal Aβ (42) and not Aβ (40) - evidence from cats and dogs. Neurobiol Aging 1996; 17: 653-9
2. 2 Games D, Adams D, Alessandrini R et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995; 373: 523-7
3. 3 Gearing M, Schneider JA, Robbins RS et al. Regional variation in the distribution of apolipoprotein E and Aβ in Alzheimer's disease. J Neuropath Exp Neurol 1995; 54: 833-41
4. 4 Gentleman SM, Greenberg BD, Savage MJ et al. Aβ42 is the predominant form of amyloid β-protein in the brains of short-term survivors of head injury. Neuroreport 1997; 8: 1519-22
5. 5 Goate A, Chartier-Harlin M-C, Mullan M et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-6
6. 6 Haass C, Schlossmacher MG, Hung AY et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 1992; 359: 322-5
7. 7 Horsburgh K, Nicoll JAR. Selective cellular alterations in amyloid precursor protein and apolipoprotein E following transient cerebral ischaemia in the rat. Alzheimer's Res 1996; 2: 37-42
8. 8 Horsburgh K, Nicoll JAR. Selective alterations in the cellular distribution of apolipoprotein E immunoreactivity following transient cerebral ischaemia in the rat. Neuropath Appl Neurobiol 1996; 22: 342-9
9. 9 Horsburgh K, Mackay K, McCulloch J. Intracortical glutamate perfusion in vivo induces cellular alterations in specific protein kinase C isoforms and amyloid precursor protein. Exp Neurol 1997; 143: 207-18
10. 10 Horsburgh K, Fitzpatrick M, Nilsen M, Nicoll JAR. Marked alterations in the cellular localisation and levels of apolipoprotein E following acute subdural hematoma in rat. Brain Res 1997; 763: 103-10
11. 11 Ishii K, Tamaoka A, Mizusawa H et al. Aβ1-40 but not Aβ1-42 levels in cortex correlate with apolipoprotein E ε4 allele dosage in sporadic Alzheimer's disease. Brain Res 1997; 748: 250-2
12. 12 Iwatsubo T, Mann DA, Odaka A, Suzuki N, Ihara Y. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down Syndrome. Ann Neurol 1995; 37: 294-9
13. 13 Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 1994; 13: 45-53
14. 14 Kida K, Golabek AA, Wisniewski T, Wisniewski KE. Regional differences in apolipoprotein E immunoreactivity in diffuse plaques in Alzheimer's disease brain. Neurosci Lett 1994; 167: 73-6
15. 15 Laskowitz D, Horsburgh K, Roses AD. Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab 1998; 18: 465-71
16. 16 Lemere CA, Blusztajn JK, Yamaguchi H et al. Sequence of deposition of heterogeneous amyloid beta-peptides of APOE in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996; 3: 16-32
17. 17 Levy-Lahad E, Wasco W, Poorkaj P et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269: 973-7
18. 1-chymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994; 372: 92-4
19. 19 Mak K, Yang F, Vinters HV, Frautschy SA, Cole GM. Polyclonals to β-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum. Brain Res 1994; 667: 138-42
20. 20 Mann DMA, Iwatsubo T, Pickering-Brown SM et al. Preferential deposition of amyloid β protein (Aβ) in the form Aβ40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Neurosci Lett 1997; 221: 81-4
21. 21 Mayeux R, Ottman R, Maestre G et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon4 in patients with Alzheimer's disease. Neurology 1995; 45: 555-7
22. 22 McNamara MJ, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease. Arch Neurol 1998; 55: 1001-4
23. 23 Mirra SS, Heyman A, McKeel D et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-86
24. 24 Mirra SS, Gearing M, McKeel DW et al. and participating neuropathologists. Interlaboratory comparison of neuropathology assessments in Alzheimer's disease: a study of the consortium to establish a registry for Alzheimer's disease (CERAD). J. Neuropath Exp Neurol 1994; 53: 303-15
25. 25 Mortimer JA, Vanduijn CM, Chandra V et al. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-controlled studies. Int J Epidem 1991; 20: S28-35
26. 26 Nicoll JAR, Roberts GW, Graham DI. Apolipoprotein E ε4 allele is associated with deposition of amyloid β-protein following head injury. Nature Med 1995; 1: 135-7
27. 27 Ohm TG, Kirca M. Bohl J, Schanagl H, Grob W, Marz W, Apolipoprolein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 1995; 65: 583-7
28. 28 Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. TINS 1994; 17: 525-30
29. 29 Rebeck GW, Reiter JS, Strickland DK, Hyman BT, Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993; 11: 575-80
30. 30 Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham D. β-Amyloid deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiat 1994; 57: 419-25
31. 31 Roses AD, Saunders A. Head injury, amyloid β and Alzheimer's disease. Nature Med 1995; 1: 603-4
32. 32 Saunders AM, Strittmatter WJ, Schmechel D et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Proc Natl Acad Sci 1993; 90: 8098-102
33. 33 Savage MJ, Kawooya JK, Pinsker LR et al. Elevated Aβ levels in Alzheimer's disease brain are associated with selective accumulation of Aβ (42) in parenchymal amyloid plaques and both Aβ (40) and Aβ (42) in cerebrovascular deposits. Int J Exp Clin Invest 1995; 2: 234-40
34. 34 Scheuner D, Eckman C, Jensen M et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med 1996; 2: 864-70
35. 35 Sheng JG, Mrak RE, Griffin WST. Apolipoprotein E distribution among different plaque types in Alzheimer's disease: implications for its role in plaque progression. Neuropath Appl Neurobiol 1996; 22: 334-41
36. 36 Sherrington R, Rogaev El, Liang Y et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754-60
37. 37 Shoji M, Golde TE, Cheung TT et al. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 1992; 258: 126-9
38. 38 Stephenson DT, Rash K, Clemens JA. Amyloid precursor protein accumulates in regions of neurodegeneration following focal cerebral ischaemia in the rat. Brain Res 1992; 593:128-35
39. 39 Strittmatter WJ, Saunders AM, Schmechel D et al. Apolipoprotein E. high avidity binding to β-amyloid and increased frequency of the E4 allele in late onset familial Alzheimer's disease. Proc Natl Acad Sci 1993; 90: 1977-81
40. 717) mutants. Science 1994; 264: 1336-40
41. 41 Teasdale GM, Nicoll JAR, Fiddes H, Murray G. Association of apoE polymorphism with outcome after head injury. Lancet 1997; 350: 1069-71
42. 42 Tekirian TL, Cole GM, Russell MJ et al. Carboxy terminal of β-amyloid deposits in aged human, canine, and polar bear brains. Neurobiol Aging 1996; 17: 249-57
43. 43 Teller JK, Russo C, DeBusk LM et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nature Med 1996; 2: 93-5
44. 44 Tomimoto H, Wakita H, Akiguchi I, Nakamura S, Kimura J. Temporal profiles of accumulation of amyloid β/A4 protein precursor in the gerbil after graded ischemic stress. J Cereb Blood Flow Metab 1994; 14: 565-73
45. 45 Wisniewski T, Frangione T. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992; 135: 235-8
46. 46 Wood SJ, Chan W, Wetzel R. Seeding of Aβ fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochem 1996; 35: 12623-8